Skip to page body Patient Care Survivorship Research Cancer Types News Giving Community Partners Clinical Trials
UCLA's Jonsson Comprehensive Cancer Center
Take the Jonsson Cancer Center Site Survey

JCCC Member Directory

Michael Roth, M.D.
Michael Roth, M.D.

Specialty:

Pulmonary Disease

General Information:

Gender:
Male
Language(s):
English

Affiliation(s):

Professor and Director, Department of Medicine, Pulmonary and Critical Care Medicine, Pulmonary Procedures Service
Member, JCCC Tumor Immunology Program Area

Education:

Fellowship:
Pulmonary Medicine, UCLA School of Medicine, 1986 - 1989
Residency:
Internal Medicine, UCLA School of Medicine, 1984 - 1986
Internship:
Internal Medicine, UCLA School of Medicine, 1983 - 1984
Medical Degree:
M.D., UCLA School of Medicine, 1983

Certification(s):

Medical Board Certification(s):
Critical Care Medicine, American Board of Internal Medicine, 1989
Pulmonary Disease, American Board of Internal Medicine, 1988
Internal Medicine, American Board of Internal Medicine, 1986

Contact Information:

Pulmonary and Critical Care Medicine:
(310) 825-8061 Information and referral
Lung Cancer Program:
(310) 794-7333 Patient appointments
Pulmonary Procedures Service:
(310) 825-5988 Information and referral
(310) 825-6301 Medical center page operator
Phone:
(310) 206-7389 Academic and research office
Email:

Practice Information:

Clinical Interest(s):
Asthma
Chronic Cough
General Pulmonology
Lung Cancer and Chest Malignancies

Scientific Interest(s):

Dr. Michael Roth's research focuses on understanding the development, regulation and function of dendritic cells and their ability to stimulate effective anti-cancer immunity. Several approaches are being investigated, including the development and testing of novel gene therapy vectors for modulating dendritic cell function and antigen-specificity, the use of cytokines (GM-CSF, IL-4) to activate and expand dendritic cells in situ within the tissues and organs of cancer patients; and the impact that inhaled drugs of abuse (marijuana and cocaine) have on the immune system. This research involves human in vitro studies, model systems and the translation of this basic research into new clinical trials in which immune-based therapy is being used to treat several types of cancer, including lung cancer and prostate cancer.

Selected Cancer-Related Publications:

Liau LM, Prins RM, Kiertscher SM, Odesa SK, Kremen TJ, Giovannone AJ, Lin JW, Chute DJ, Mischel PS, Cloughesy TF, Roth MD. Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res. 2005; 11(15): 5515-25.

Basak SK, Harui A, Stolina M, Sharma S, Mitani K, Dubinett S, Roth MD. Increased dendritic cell number and function following continuous in vivo infusion of GM-CSF and IL-4. Blood. 2002; 99(8):2869-2879.

Kiertscher SM, Lou J, Dubinett SM, Roth MD. Tumors promote altered maturation and early apoptosis of monocyte-derived dendritic cells. J Immunol. 2000; 164:1269-1276.

Roth MD, Gitlitz BJ, Kiertscher SM, Park AN, Mendenhall M, Moldawer N, Figlin RA. Granulocyte/macrophage-colony stimulating factor and interleukin-4 enhance the number and antigen-presenting activity of circulating CD14+ and CD83+ cells in cancer patients. Cancer Res. 2000; 60(7):1934-1941.

Kiertscher SM, Roth MD. Human CD14+ leukocytes acquire the phenotype and function of antigen-presenting dendritic cells when cultured in GM-CSF and IL-4. J Leukoc Biol. 1996; 59:208-218.